Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Indinavir/Ritonavir + 2 NRTIs in HIV-1
NCT00005118Phase 2Unknown
- Sponsor
- Merck & Co.
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of indinavir in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Merck & Co. Primary endpoints: Plasma viral RNA at 24 weeks and CD4 cell counts at 24 weeks. Status: unknown.
02
Drugs
indinavir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT00005118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005118.